drugset
Drugs / 6-diazo-5-oxo-L-norleucine
last change Jan 2024 re-read 3 minutes ago

6-diazo-5-oxo-L-norleucine

also known as DON

Small molecule

Developed for
cerebral malaria
Investigated by
Douglas Postels, MD, MS · National Institute of Allergy and Infectious Diseases (NIAID)

Trials 1

today NCT05478720 · Ph 1/2
20232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05478720 Aug 2022 → Dec 2026 expected cerebral malaria Douglas Postels, MD, MS Recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as 6-diazo-5-oxo-L-norleucine ClinicalTrials.gov intervention name — accepted as the source's own label NCT05478720 ↗
Known as DON “This trial aims to establish the preliminary safety of one such novel therapy, the glutamine antagonist 6-diazo-5-oxo-L-norleucine (DON).” PMID 38279124 ↗ Jan 2024
Modality Small molecule — CHEMBL97485 ↗
Route Intravenous “a single dose of intravenous (IV) DON is administered” PMID 38279124 ↗ Jan 2024